Your browser doesn't support javascript.
loading
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
Borelli, Beatrice; Moretto, Roberto; Lonardi, Sara; Bonetti, Andrea; Antoniotti, Carlotta; Pietrantonio, Filippo; Masi, Gianluca; Burgio, Valentina; Marmorino, Federica; Salvatore, Lisa; Rossini, Daniele; Zaniboni, Alberto; Zucchelli, Gemma; Martignetti, Angelo; Di Battista, Monica; Pella, Nicoletta; Passardi, Alessandro; Boccaccino, Alessandra; Leone, Francesco; Colombo, Camilla; Granetto, Cristina; Vannini, Francesca; Marsico, Valentina Angela; Martinelli, Erika; Antonuzzo, Lorenzo; Vitello, Stefano; Delliponti, Laura; Boni, Luca; Cremolini, Chiara; Falcone, Alfredo.
Afiliação
  • Borelli B; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Moretto R; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Lonardi S; Department of Clinical and Experimental Oncology, SC Medical Oncology Unit 1, Istituto Oncologico Veneto - IRCCS, Padua, Italy.
  • Bonetti A; Department of Oncology, "Mater Salutis" Hospital, Legnago, Italy.
  • Antoniotti C; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Masi G; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Burgio V; Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy.
  • Marmorino F; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Salvatore L; Medical Oncology Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Rossini D; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Zaniboni A; Medical Oncology Unit, Fondazione Poliambulanza, Brescia, Italy.
  • Zucchelli G; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Martignetti A; Oncology Department, Azienza Usl Toscana Sud Est, Siena, Italy.
  • Di Battista M; Department of Medical Oncology, Azienda USL, Bologna, Italy.
  • Pella N; Department of Medical Oncology, Azienda Sanitaria Universitaria Integrata, Udine, Italy.
  • Passardi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Boccaccino A; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Leone F; Department of Medical Oncology, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Italy.
  • Colombo C; Department of Oncology, University of Turin, Turin, Italy.
  • Granetto C; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Vannini F; Department of Medical Oncology, A.O. S. Croce and Carle Teaching Hospital, Cuneo, Italy.
  • Marsico VA; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Martinelli E; Unit of Medical Oncology, Hospital San Giovanni Calibita Fatebenefratelli, Rome, Italy.
  • Antonuzzo L; Department of Internal and Experimental Medicine "F. Magrassi e A. Lanzara", Institute of Medical Oncology, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Vitello S; S.C. Oncologia Medica 1, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • Delliponti L; Medical Genetics, University of Siena, Siena, Italy.
  • Boni L; Department of Medical Oncology, Sant'Elia Hospital, Caltanissetta, Italy.
  • Cremolini C; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Falcone A; Clinical Trial Center, AOU Careggi, Firenze, Italy.
ESMO Open ; 3(4): e000403, 2018.
Article em En | MEDLINE | ID: mdl-30018814
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article